A brain organoid that can learn to play Pac-Man sounds like a stunt until you realize what it represents: measurable learning, rewiring, and human-relevant neural function that animal models often fail to predict. We talk with Dr. Lowry Curley, founder of Luna LifeSci and former CEO and co-founder of Axosim (now 28 Bio), about why neuroscience drug development breaks so often and how NAMs are finally giving teams better tools to make safer calls earlier.
If you’re building in biotech, investing in drug discovery, or just trying to understand what replaces animal testing next, this conversation gives you a clear map of the technology, the incentives, and the milestones to watch. Subscribe, share this with a colleague, and leave a review with the biggest NAM question you want answered next.
Podden och tillhörande omslagsbild på den här sidan tillhör
3DHEALS. Innehållet i podden är skapat av 3DHEALS och inte av,
eller tillsammans med, Poddtoppen.
